Pevion Biotech appoints new CEO and secures CHF 10 Million financing
Pevion Biotech AG announced the appointment of Evert Kueppers as its new Chief Executive Officer, succeeding Thomas Stauffer.
Prior to joining Pevion, Evert Kueppers was CEO of Pieris AG, a Munich-based biotechnology company, which he successfully restructured and refinanced raising a total of US$ 45 million. Before that, Evert was Head of Business Development at IDEA AG, where he was instrumental in corporate development and partnering activities.
Before joining the biotech industry, he spent several years in the International Operations of BASF Pharma (now Abbott Labs) and was a management consultant with the global health care team of AT Kearney in London. Evert holds an advanced degree in Biomedical Sciences from Leiden University and an MBA from RSM/Erasmus University. He currently also serves on the Board of Cenix Bioscience. At the same time, the Company secured further financing commitments of CHF 10 million from its existing investors, BZ Bank, BB Biotech Ventures and Core Capital.
Pevion plans to raise additional financing over the next twelve months to broaden and further its pipeline.
Other news from the department people
